The introduction of a new class of anti-HIV agents, the protease inhibitors, has given new hope to patients with HIV infection. Use of these agents requires the pharmacist to have a complete knowledge of phar macokinetics, adverse reactions, drug-drug interactions, and resistance profiles. Patient compliance is one of the most important factors affecting the success and failure of protease inhibitor therapy. Pharma cists have the opportunity to positively influence outcomes of HIV therapy.
Get full access to this article
View all access options for this article.
References
1.
Acosta E., Fletcher C.Agents for treating human immunodeficiency virus infection. AM J Hosp Pharm1994;51:2251-67
2.
Lipsky J.Antiretroviral drugs for AIDS. Lancet1996 ;348:800-3
3.
Hirsch M., D'Aquila R.Therapy for human immunodeficiency virus infection. N Engl J Med1993;328:1686-95
4.
Saag M.AIDS testing now and in the future. In Sande M, Volberding P, eds. The Medical Management of AIDS. Philadelphia, W. B. Saunders Co., 1995:65-88
5.
Mellors J., Rinaldo C., Gupta P., et al.Prognosis in HIV-1 infection predicted by the quantity of virus in plasma . Science1996;272:1167-70
6.
Kuritzkes D.Plasma HIV RNA quantitation. Improving the Management of HIV Disease1996;4(2):11-14
7.
Mellors J.Viral load—The key to disease progression. As presented in HIV in Focus: A Daily Reporting Service from the XI International Conference on AIDS; July 7-12 Vancouver, Canada. 1996;2:3
8.
Mellors J.Plasma viral load and CD4 T-lymphocyte counts predict clinical outcomes . As presented in HIV in Focus: A Daily Reporting Service from the XI International Conference on AIDS; July 7-12 Vancouver, Canada. 1996;1:6
9.
Voelker R.Can researchers use new drugs to push HIV envelope to extinction?JAMA1996;276(6):435-437
10.
Carpenter C. , Fischl M., Hammer S., et al.Antiretroviral therapy for HIV infection in 1996. JAMA1996 ;276(2):146-154
11.
Saag M., Holodniy M., Kuritzkes D.HIV viral load markers in clinical practice. Nature Medicine1996;2(6):625-9
12.
Carpenter C. , Volberding P., Richman D., et al.Bringing state of the art guidelines to clinical practice. As presented in HIV in Focus: A Daily Reporting Service from the XI International Conference on AIDS; July 7-12 Vancouver , Canada. 1996;5:7-8
13.
Richman D.New strategies to combat HIV drug resistance. Hospital Practice1996;August 15:47-58
14.
Montaner J.Chairman underlines confidence in combination therapy. As presented in HIV in Focus: A Daily Reporting Service from the XI International Conference on AIDS; July 7-12 Vancouver, Canada. 1996; 2:1
15.
Gerber, J.Drug interactions with HIV protease inhibitors. Improving the Management of HIV disease. 1996;4:20-3
Salgo M., Beattie D., Bragman K., et al.Saquinavir (Invirase SQV) vs. Hivid (Zalcitabine, ddC) vs. combination as treatment for advanced HIV infection in patients discontinuing/unable to take retrovir (Zidovudine, ZDV. Presented at the XI International Conference on AIDS; July 7-12; Vancouver , Canada
19.
Noble S., Faulds D.Saquinavir: A review of its pharmacology and clinical potential in the management of HIV infection. Drugs1996 ;52(1):94-112
20.
Saquinavir Data on File. Hoffman-La Roche Inc., Nutley, NJ
21.
Saquinavir Investigation Drug Brochure. Hoffman-La Roche, Nutley, NJ
22.
Collier A., Coombs R., Schoenfeld D., et al.Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med1996;334:1011-7
23.
Cameron B.Synergistic action between ritonavir and saquinavir: implications for treatment . As presented in Satellite Symposium Highlights from the XI International Conference on AIDS; July 11 Vancouver, Canada. 1996:6
24.
New antiretroviral agents: Review and recommendations. HIV Clinical Information Network1996, July
25.
Rodvold K., Meyer J.Drug-food interactions with grapefruit juice. Infect Med1996; 13(10):868, 871-3,912
26.
Ritonavir Product Labeling. Abbott LaboratoriesNorth Chicago, IL
27.
Markowitz, M., Saag M., Powderly W., et al.A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection . N Engl J Med1995;333:1534-9
28.
Ritonavir Data on File. Abbott Laboratories, North Chicago, IL
29.
Danner S.Ritonavir phase III studies: overview. As presented in Satellite Symposium Highlights from the XI International Conference on AIDS; July 11 Vancouver, Canada. 1996 ;3-4
30.
Katlarna C.Triple therapy with ritonavir, ddC, and AZT: study update. As presented in Satellite Symposium Highlights from the XI International Conference on AIDS; July 11 Vancouver, Canada. 1996;4-5
31.
Benson C.New directions in chemoprophylaxis and treatment of disseminated Mycobacterium avium complex disease. Presentation at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy . 1996. New Orleans, LA
32.
Indinavir Product Labeling. Merck & Co., Inc., West Point, PA
33.
Indinavir Data on File. Merck & Co., Inc., West Point, PA
34.
Press Release September 16, 1996. Agouron Pharmaceuticals, La Jolla, CA
35.
Nelfinavir. Data on file. Agouron Pharmaceuticals , La Jolla, CA
36.
Press Release January 30, 1996. Agouron Pharmaceuticals , La Jolla, CA
37.
Press Release May 20, 1996. Agouron Pharmaceuticals , La Jolla, CA
38.
Press Release July 8, 1996. Agouron Pharmaceuticals , La Jolla, CA
39.
Emini E., Salgo M., Moyle G.Focus on protease inhibitors. As presented in HIV in Focus: A Daily Reporting Service from the XI International Conference on AIDS; July 7-12 Vancouver, Canada. 1996;3:3
40.
Markowitz M.Protease Inhibitors: A new family of drugs for the treatment of HIV infection. International Association of Physicians in AIDS care. 1996;1-16
41.
Resistance review: Highlights from the 5th international workshop; July 3-6 Whistler, Canada. 1996:1-4
42.
Miles S., Squires K.Protease inhibitors. Improving the Management of HIV Disease1996;4(1):7-9
43.
Schapiro J.Possible causes of long-term failure of therapy with protease inhibitors . As presented in HIV in Focus: A Daily Reporting Service from the XI International Conference on AIDS; July 7-12 Vancouver, Canada. 1996,3:8
44.
Molla A.Ritonavir resistance dependent upon plasma concentration. As presented in HIV in Focus: A Daily Reporting Service from the XI International Conference on AIDS; July 7-12 Vancouver , Canada. 1996;1:7-8
45.
Condra J.Protease inhibitor benefits limited by cross-resistance. As presented in HIV in Focus: A Daily Reporting Service from the XI International Conference on AIDS; July 7-12 Vancouver, Canada. 1996;1:4
46.
Patrick A.Nelfinavir: characterization of early resistance. As presented in HIV in Focus: A Daily Reporting Service from the XI International Conference on AIDS; July 7-12 Vancouver , Canada. 1996;1:3
47.
Saag M.Nelfinavir—A unique resistance profile ?As presented in HIV in Focus: A Daily Reporting Service from the XI International Conference on AIDS; July 7-12 Vancouver, Canada. 1996,3:7
48.
Volberding P.Combination therapy—Making rational choices . As presented in HIV in focus: A Daily Reporting Service from the XI International Conference on AIDS; July 7-12 Vancouver, Canada. 1996;2:1-2
49.
Vella S., Fischl M.Suppression of viral replication—The rational approach to therapy . As presented in HIV in Focus: A Daily Reporting Service from the XI International Conference on AIDS; July 7-12 Vancouver , Canada. 1996;3:4
50.
Lange J.Two nucleosides and a protease—The new standard of care. As presented in HIV in Focus: A Daily Reporting Service from the XI International Conference on AIDS; July 7-12 Vancouver , Canada. 1996;2:8
51.
New drugs for HIV infection. The Medical Letter on Drugs and Therapeutics. 1996;38(972): 35-38
